NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $656.11
  • Forecasted Upside: 25.31 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$523.58
▼ -3.91 (-0.74%)
1 month | 3 months | 12 months
Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$656.11
▲ +25.31% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $656.11, with a high forecast of $800.00 and a low forecast of $495.00. The average price target represents a 25.31% upside from the last price of $523.58.

Buy

The current consensus among 16 contributing investment analysts is to buy stock in Regeneron Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 14 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 16 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/23/2020
  • 1 strong buy ratings
  • 18 buy ratings
  • 8 hold ratings
  • 0 sell ratings
6/21/2020
  • 1 strong buy ratings
  • 18 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/19/2020
  • 1 strong buy ratings
  • 16 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/18/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021SVB LeerinkLower Price TargetOutperform$657.00 ➝ $641.00Low
i
5/7/2021Morgan StanleyBoost Price TargetEqual Weight$477.00 ➝ $495.00Low
i
4/19/2021Morgan StanleyLower Price TargetEqual Weight$525.00 ➝ $477.00Low
i
4/13/2021Robert W. BairdReiterated RatingHoldLow
i
4/13/2021Canaccord GenuityReiterated RatingBuyLow
i
3/26/2021SVB LeerinkBoost Price TargetOutperform$655.00 ➝ $657.00High
i
3/24/2021Canaccord GenuityReiterated RatingBuyHigh
i
2/24/2021Canaccord GenuityReiterated RatingBuyMedium
i
2/23/2021Credit Suisse GroupBoost Price TargetOutperform$753.00 ➝ $760.00High
i
2/16/2021Cantor FitzgeraldLower Price TargetOverweight$696.00 ➝ $656.00Low
i
2/8/2021Morgan StanleyLower Price TargetEqual Weight$553.00 ➝ $525.00Medium
i
2/8/2021Credit Suisse GroupLower Price TargetOutperform$758.00 ➝ $753.00Medium
i
2/8/2021CowenLower Price TargetOutperform$684.00 ➝ $565.00High
i
2/8/2021SVB LeerinkBoost Price TargetOutperform$623.00 ➝ $640.00High
i
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$630.00Medium
i
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$527.00 ➝ $553.00Low
i
1/14/2021Smith Barney CitigroupBoost Price Target$575.00 ➝ $584.00Low
i
1/14/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$575.00 ➝ $584.00Low
i
1/13/2021BenchmarkUpgradeHold ➝ Buy$590.00Medium
i
1/8/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ Buy$635.00 ➝ $575.00Medium
i
1/8/2021FIXUpgradeNeutral ➝ Buy$635.00 ➝ $575.00Medium
i
12/16/2020Morgan StanleyLower Price TargetEqual Weight$602.00 ➝ $527.00Low
i
12/16/2020Credit Suisse GroupLower Price TargetOutperform$737.00 ➝ $736.00Medium
i
11/9/2020Morgan StanleyLower Price TargetEqual Weight$609.00 ➝ $602.00High
i
11/6/2020TruistBoost Price Target$750.00 ➝ $770.00Low
i
11/6/2020Credit Suisse GroupLower Price TargetOutperform$745.00 ➝ $737.00Low
i
11/6/2020SVB LeerinkBoost Price TargetOutperform$650.00 ➝ $653.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
11/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$626.00 ➝ $630.00Low
i
10/13/2020Morgan StanleyLower Price TargetEqual Weight$611.00 ➝ $609.00Low
i
10/6/2020SVB LeerinkBoost Price TargetOutperform$629.00 ➝ $650.00High
i
Rating by Geoff Porges at SVB Leerink LLC
10/5/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$690.00High
i
10/1/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
8/20/2020BenchmarkDowngradeBuy ➝ HoldHigh
i
Rating by Aydin Huseynov at Benchmark Co.
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$716.00 ➝ $725.00Low
i
8/6/2020BarclaysBoost Price Target$615.00 ➝ $675.00Low
i
8/6/2020Morgan StanleyLower Price TargetEqual Weight$619.00 ➝ $611.00Low
i
8/6/2020OppenheimerBoost Price TargetOutperform$675.00 ➝ $725.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/6/2020CitigroupBoost Price TargetNeutral$585.00 ➝ $635.00Low
i
8/6/2020BMO Capital MarketsBoost Price TargetOutperform$525.00 ➝ $626.00Low
i
8/5/2020The Goldman Sachs GroupBoost Price Target$700.00 ➝ $800.00Low
i
8/5/2020Piper SandlerBoost Price TargetOverweight$630.00 ➝ $675.00High
i
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$700.00 ➝ $716.00High
i
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$555.00 ➝ $619.00Low
i
7/8/2020SunTrust BanksUpgradeHold ➝ Buy$400.00 ➝ $750.00Low
i
7/8/2020Canaccord GenuityBoost Price TargetBuy$600.00 ➝ $700.00Low
i
7/1/2020OppenheimerBoost Price TargetOutperform$625.00 ➝ $675.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/24/2020Credit Suisse GroupBoost Price TargetOutperform$605.00 ➝ $700.00High
i
6/12/2020Jefferies Financial GroupBoost Price TargetBuy$657.00 ➝ $691.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020Jefferies Financial GroupReiterated RatingBuy$657.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2020CowenReiterated RatingHold$584.00Low
i
Rating by Yaron Werber at Cowen Inc
6/2/2020OppenheimerReiterated RatingBuy$625.00Low
i
6/2/2020Cantor FitzgeraldBoost Price TargetNeutral$400.00 ➝ $624.00Low
i
5/28/2020BarclaysBoost Price Target$530.00 ➝ $615.00High
i
5/27/2020CfraLower Price TargetHold$557.00 ➝ $549.00Low
i
5/27/2020SVB LeerinkBoost Price TargetOutperform$622.00 ➝ $625.00High
i
Rating by Geoff Porges at SVB Leerink LLC
5/26/2020SVB LeerinkReiterated RatingBuy$622.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/26/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$559.00 ➝ $734.00High
i
5/6/2020Robert W. BairdBoost Price TargetNeutral ➝ Neutral$487.00 ➝ $510.00High
i
5/6/2020Canaccord GenuityBoost Price TargetBuy$575.00 ➝ $630.00High
i
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$466.00 ➝ $525.00High
i
5/6/2020Royal Bank of CanadaLower Price Target$533.00 ➝ $524.00Medium
i
5/6/2020Piper SandlerBoost Price Target$550.00 ➝ $600.00Low
i
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $555.00Medium
i
5/6/2020OppenheimerBoost Price TargetOutperform$525.00 ➝ $625.00High
i
5/6/2020Credit Suisse GroupBoost Price TargetOutperform$596.00 ➝ $605.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
5/6/2020The Goldman Sachs GroupBoost Price TargetConviction-Buy$636.00 ➝ $700.00High
i
5/6/2020SVB LeerinkBoost Price TargetOutperform$604.00 ➝ $622.00High
i
5/1/2020Piper SandlerReiterated RatingOverweightLow
i
4/28/2020Canaccord GenuityBoost Price TargetBuy$550.00 ➝ $575.00Medium
i
4/28/2020CitigroupDowngradeBuy ➝ Neutral$540.00 ➝ $575.00High
i
4/19/2020BenchmarkInitiated CoverageHoldLow
i
Rating by Aydin Huseynov at Benchmark Co.
4/17/2020BMO Capital MarketsBoost Price TargetMarket Perform$379.00 ➝ $466.00High
i
4/17/2020BenchmarkUpgradeHold ➝ Buy$655.00High
i
4/15/2020Morgan StanleyLower Price TargetEqual Weight$410.00 ➝ $409.00Medium
i
4/15/2020JPMorgan Chase & Co.Boost Price TargetNeutral$375.00 ➝ $429.00Medium
i
4/8/2020BenchmarkInitiated CoverageHoldMedium
i
4/7/2020SVB LeerinkBoost Price TargetOutperform$600.00 ➝ $604.00Medium
i
4/6/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$370.00 ➝ $435.00Low
i
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$455.00High
i
3/12/2020ArgusBoost Price TargetBuy$430.00 ➝ $540.00High
i
Rating by Jasper Hellweg at Argus
3/11/2020OppenheimerBoost Price TargetOutperform$450.00 ➝ $525.00Medium
i
3/4/2020CfraBoost Price TargetBuy ➝ Hold$460.00 ➝ $487.00High
i
3/4/2020Piper SandlerBoost Price Target$435.00 ➝ $500.00High
i
2/28/2020CowenBoost Price TargetMarket Perform$386.00 ➝ $495.00High
i
Rating by Yaron Werber at Cowen Inc
2/28/2020CitigroupBoost Price TargetBuy$420.00 ➝ $540.00High
i
2/27/2020BarclaysInitiated CoverageOverweight$530.00High
i
2/26/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
i
2/26/2020Credit Suisse GroupBoost Price TargetTop Pick ➝ Outperform$420.00 ➝ $510.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
2/26/2020Robert W. BairdDowngradeOutperform ➝ Neutral$410.00High
i
2/26/2020Canaccord GenuityUpgradeHold ➝ Buy$409.00 ➝ $550.00High
i
Rating by John Newman at Canaccord Genuity
2/25/2020Jefferies Financial GroupUpgradeHold ➝ Buy$355.00 ➝ $492.00High
i
2/24/2020Evercore ISIUpgradeIn-Line ➝ Outperform$500.00High
i
Rating by Joshua Schimmer at Evercore ISI
2/11/2020ArgusUpgradeHold ➝ Buy$430.00Medium
i
2/7/2020Evercore ISIInitiated CoverageHold$400.00Low
i
Rating by Joshua Schimmer at Evercore ISI
2/7/2020Morgan StanleyLower Price TargetEqual Weight$411.00 ➝ $410.00Low
i
2/7/2020SunTrust BanksBoost Price TargetHold$400.00High
i
1/22/2020OppenheimerBoost Price TargetOutperform$430.00 ➝ $450.00Low
i
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$387.00 ➝ $411.00Low
i
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
i
Rating by Dane Leone at Raymond James
12/13/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
i
Rating by Evan Seigerman at Credit Suisse Group AG
12/9/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
i
11/12/2019SunTrust BanksInitiated CoverageHold$360.00Medium
i
11/11/2019Evercore ISIReiterated RatingBuy$395.00Low
i
11/6/2019CitigroupUpgradeNeutral ➝ Buy$340.00 ➝ $420.00Low
i
11/6/2019OppenheimerLower Price Target$480.00 ➝ $430.00Low
i
11/6/2019BMO Capital MarketsBoost Price TargetMarket Perform$344.00 ➝ $358.00Medium
i
Rating by Matthew Luchini at BMO Capital Markets
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$375.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2019Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$310.00 ➝ $340.00Medium
i
10/16/2019Bank of AmericaInitiated CoverageNeutral$325.00Low
i
10/9/2019Canaccord GenuityLower Price TargetHold$353.00 ➝ $320.00Medium
i
10/8/2019CowenSet Price TargetHold$349.00Low
i
Rating by Yaron Werber at Cowen Inc
10/8/2019Piper Jaffray CompaniesSet Price TargetBuy$435.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
10/8/2019BMO Capital MarketsSet Price TargetHold$344.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$355.00 ➝ $403.00Low
i
8/7/2019Robert W. BairdUpgradeNeutral ➝ Outperform$410.00Low
i
8/7/2019Credit Suisse GroupLower Price TargetNeutral$333.00 ➝ $325.00Low
i
8/7/2019BMO Capital MarketsLower Price TargetMarket Perform$344.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/29/2019CowenReiterated RatingHold$353.00Medium
i
6/21/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/18/2019ArgusDowngradeBuy ➝ HoldHigh
i
6/14/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/11/2019SVB LeerinkSet Price TargetBuy$453.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/23/2019CitigroupLower Price TargetNeutral ➝ Neutral$396.00 ➝ $340.00Low
i
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$336.00High
i
5/13/2019Cantor FitzgeraldLower Price TargetNeutral$441.00 ➝ $405.00Medium
i
5/8/2019BMO Capital MarketsLower Price TargetPositive ➝ Market Perform$412.00 ➝ $375.00Medium
i
5/8/2019Morgan StanleyLower Price TargetEqual Weight$420.00 ➝ $389.00Medium
i
5/8/2019Canaccord GenuityReiterated RatingHold ➝ Hold$408.00 ➝ $353.00High
i
5/8/2019UBS GroupLower Price TargetBuy$480.00 ➝ $440.00Medium
i
5/7/2019Piper Jaffray CompaniesReiterated RatingOverweight$435.00Medium
i
5/7/2019CowenReiterated RatingHold$353.00Medium
i
4/17/2019Jefferies Financial GroupLower Price TargetHold$376.00 ➝ $343.00High
i
2/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$487.00Medium
i
2/22/2019GuggenheimDowngradeBuy ➝ Neutral$466.00 ➝ $425.00Low
i
Rating by Adnan Butt at Guggenheim
2/7/2019OppenheimerBoost Price TargetOutperform$440.00 ➝ $480.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/7/2019BMO Capital MarketsBoost Price TargetMarket Perform$412.00Low
i
2/6/2019Cantor FitzgeraldReiterated RatingHold$441.00High
i
1/7/2019CowenReiterated RatingHold$385.00Low
i
1/4/2019GuggenheimUpgradeNeutral ➝ Buy$461.00High
i
12/13/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
i
12/7/2018SVB LeerinkSet Price TargetBuy$473.00 ➝ $483.00Low
i
12/2/2018OppenheimerSet Price TargetBuy$440.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/13/2018ArgusReiterated RatingBuyLow
i
11/7/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/6/2018CowenReiterated RatingHold$385.00Medium
i
10/22/2018CowenReiterated RatingHold$385.00Medium
i
10/22/2018Cantor FitzgeraldBoost Price TargetNeutral$441.00Low
i
10/22/2018JPMorgan Chase & Co.Set Price TargetHold$405.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$409.00 ➝ $412.00High
i
10/11/2018Canaccord GenuityBoost Price TargetHold$390.00 ➝ $410.00High
i
10/2/2018JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
10/1/2018SVB LeerinkBoost Price TargetOutperform$506.00 ➝ $512.00High
i
Rating by Geoff Porges at SVB Leerink LLC
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$415.00High
i
8/16/2018CowenReiterated RatingHold$385.00Low
i
8/6/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$290.00 ➝ $305.00Low
i
Rating by Geoff Meacham at Barclays PLC
8/3/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$304.00 ➝ $390.00Low
i
8/3/2018SunTrust BanksReiterated RatingHold$400.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$396.00 ➝ $409.00Low
i
8/3/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
i
8/2/2018BMO Capital MarketsSet Price TargetHold$388.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/24/2018Jefferies Financial GroupReiterated RatingHold$340.00Medium
i
7/19/2018Canaccord GenuityReiterated Rating$367.74$304.00Low
i
7/16/2018ArgusBoost Price TargetBuy ➝ Buy$383.00 ➝ $415.00Low
i
7/13/2018Morgan StanleyBoost Price TargetEqual Weight$370.00 ➝ $396.00Low
i
7/2/2018SunTrust BanksSet Price TargetHold$344.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
6/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$325.00High
i
6/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
i
5/23/2018BarclaysSet Price TargetSell$290.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/7/2018Royal Bank of CanadaLower Price TargetSector Perform$342.00Low
i
5/5/2018Credit Suisse GroupSet Price TargetBuy$420.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/4/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$400.00 ➝ $370.00Low
i
5/4/2018Canaccord GenuityLower Price TargetHold ➝ Hold$356.00 ➝ $304.00Low
i
5/4/2018SVB LeerinkSet Price TargetBuy$502.00 ➝ $435.00Low
i
5/4/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$398.00 ➝ $361.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/4/2018CowenReiterated RatingOutperform$400.00 ➝ $350.00Low
i
5/4/2018SunTrust BanksLower Price TargetHold$344.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
5/3/2018BarclaysSet Price TargetSell$290.00Low
i
Rating by Geoff Meacham at Barclays PLC
5/1/2018GuggenheimDowngradeBuy ➝ NeutralLow
i
Rating by Adnan Butt at Guggenheim
4/27/2018Credit Suisse GroupSet Price TargetBuy$420.00High
i
Rating by Alethia Young at Credit Suisse Group AG
4/27/2018CowenReiterated RatingHold$400.00Low
i
4/17/2018Credit Suisse GroupLower Price TargetBuy$440.00 ➝ $420.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLow
i
4/9/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
i
3/13/2018BTIG ResearchReiterated RatingHoldMedium
i
3/13/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$367.00Medium
i
Rating by Navin Jacob at Deutsche Bank Aktiengesellschaft
2/21/2018Canaccord GenuityDowngradeBuy ➝ Hold$522.00 ➝ $356.00Medium
i
2/13/2018BTIG ResearchReiterated RatingHoldHigh
i
2/9/2018SunTrust BanksSet Price TargetHold$430.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
2/9/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$401.00 ➝ $415.00High
i
2/9/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$568.00 ➝ $502.00High
i
2/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
i
2/9/2018GuggenheimSet Price TargetBuy$530.00High
i
2/8/2018Jefferies Financial GroupReiterated RatingNeutral ➝ Hold$380.00High
i
2/8/2018BTIG ResearchDowngradeBuy ➝ Neutral$480.00High
i
2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$398.00 ➝ $444.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
2/7/2018Credit Suisse GroupSet Price TargetBuy$440.00High
i
Rating by Alethia Young at Credit Suisse Group AG
2/7/2018CowenReiterated RatingHold$450.00High
i
2/7/2018Canaccord GenuityReiterated RatingBuy$522.00High
i
Rating by John Newman at Canaccord Genuity
2/2/2018Jefferies Financial GroupReiterated RatingHold$421.00Medium
i
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$455.00 ➝ $457.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/9/2018CitigroupReiterated RatingNeutral ➝ Neutral$380.00 ➝ $388.00High
i
12/28/2017ArgusLower Price TargetPositive ➝ Buy$540.00 ➝ $470.00Low
i
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00Low
i
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$397.00Medium
i
12/1/2017CitigroupDowngradeBuy ➝ Neutral$480.00 ➝ $380.00High
i
11/28/2017JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/28/2017BTIG ResearchLower Price TargetBuy ➝ Buy$520.00 ➝ $480.00Low
i
11/27/2017BMO Capital MarketsSet Price TargetHold$444.00High
i
Rating by Matthew Luchini at BMO Capital Markets
11/22/2017BTIG ResearchReiterated RatingBuy$520.00Low
i
11/16/2017Evercore ISILower Price TargetOutperform$605.00 ➝ $445.00N/A
i
Rating by Josh Schimmer at Evercore ISI
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/9/2017Morgan StanleyLower Price TargetEqual Weight$490.00 ➝ $463.00N/A
i
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$473.00 ➝ $425.00N/A
i
11/9/2017BMO Capital MarketsLower Price TargetMarket Perform$491.00 ➝ $479.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
11/9/2017CitigroupReiterated RatingBuy$480.00N/A
i
11/3/2017Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
i
10/31/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$540.00N/A
i
10/20/2017BarclaysDowngradeEqual Weight ➝ Underweight$450.00 ➝ $395.00N/A
i
10/16/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/16/2017Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
10/6/2017Morgan StanleyReiterated RatingEqual Weight$450.00 ➝ $490.00N/A
i
10/6/2017Jefferies Financial GroupReiterated RatingHold$471.00 ➝ $500.00N/A
i
10/2/2017SunTrust BanksReiterated RatingHold$435.00Medium
i
9/29/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$540.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/27/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/21/2017UBS GroupLower Price TargetBuy$535.00 ➝ $500.00Medium
i
Rating by Carter Gould at UBS Group AG
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$475.00Medium
i
9/11/2017Canaccord GenuityReiterated RatingBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
9/8/2017Robert W. BairdReiterated RatingSell$408.00Low
i
9/7/2017CitigroupReiterated RatingBuy$575.00Low
i
9/6/2017Raymond JamesReiterated RatingOutperform ➝ Outperform$566.00Low
i
8/23/2017Morgan StanleyReiterated RatingEqual Weight$450.00Low
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$605.00Medium
i
8/15/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/15/2017SVB LeerinkReiterated RatingOutperform ➝ Positive$580.00 ➝ $552.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/14/2017Canaccord GenuitySet Price TargetBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
8/9/2017Jefferies Financial GroupReiterated RatingHold$418.00 ➝ $471.00Low
i
8/9/2017The Goldman Sachs GroupReiterated RatingNeutral$469.00 ➝ $472.00Low
i
8/9/2017JPMorgan Chase & Co.Reiterated RatingHold$427.00 ➝ $455.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017SVB LeerinkReiterated RatingOutperform$573.00 ➝ $580.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/8/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00Low
i
8/4/2017UBS GroupReiterated RatingBuy ➝ Buy$489.00 ➝ $535.00Low
i
Rating by Carter Gould at UBS Group AG
8/4/2017CitigroupBoost Price TargetBuy$555.00 ➝ $575.00Low
i
8/3/2017BMO Capital MarketsSet Price TargetHold$491.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
8/3/2017Canaccord GenuitySet Price TargetBuy$522.00Low
i
Rating by John Newman at Canaccord Genuity
8/3/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/1/2017Piper Jaffray CompaniesReiterated RatingOverweight$557.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/1/2017Robert W. BairdDowngradeNeutral ➝ Underperform$408.00High
i
7/31/2017BMO Capital MarketsReiterated RatingMarket Perform$484.00High
i
Rating by Matthew Luchini at BMO Capital Markets
7/28/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$484.00 ➝ $522.00Low
i
Rating by John Newman at Canaccord Genuity
7/22/2017BarclaysReiterated RatingEqual Weight$400.00 ➝ $450.00Low
i
7/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00 ➝ $484.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 ➝ $593.00Low
i
7/14/2017Credit Suisse GroupDowngradeHold$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
7/10/2017Morgan StanleyReiterated RatingEqual Weight$405.00 ➝ $450.00Medium
i
6/30/2017BTIG ResearchReiterated RatingBuy ➝ Buy$480.00 ➝ $540.00High
i
6/28/2017SVB LeerinkReiterated RatingOutperform$493.00 ➝ $573.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
6/26/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$410.00 ➝ $480.00Low
i
6/22/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$573.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
6/22/2017Raymond JamesReiterated RatingOutperform$475.00 ➝ $547.00Medium
i
6/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
6/20/2017Canaccord GenuitySet Price TargetBuy$484.00Low
i
Rating by John Newman at Canaccord Genuity
6/20/2017Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$446.00 ➝ $557.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/14/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/13/2017SVB LeerinkReiterated RatingOutperform$493.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
5/25/2017Sanford C. BernsteinReiterated RatingOutperformHigh
i
5/15/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/15/2017CowenReiterated RatingHold$380.00Low
i
Rating by Phil Nadeau at Cowen Inc
5/15/2017BMO Capital MarketsBoost Price TargetHold$412.00 ➝ $421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/8/2017BarclaysBoost Price TargetEqual Weight$375.00 ➝ $400.00Low
i
5/5/2017Credit Suisse GroupReiterated RatingBuy$485.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/5/2017UBS GroupSet Price TargetBuy$446.00 ➝ $489.00N/A
i
Rating by Carter Gould at UBS Group AG
5/5/2017Canaccord GenuityUpgradeHold ➝ Buy$375.00 ➝ $484.00Low
i
Rating by John Newman at Canaccord Genuity
5/5/2017CowenReiterated RatingHold$380.00Low
i
Rating by Phil Nadeau at Cowen Inc
5/5/2017BMO Capital MarketsReiterated RatingHold$412.00 ➝ $421.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
5/4/2017OppenheimerReiterated RatingHoldLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/12/2017Jefferies Financial GroupReiterated RatingHold$357.00Low
i
3/30/2017Canaccord GenuityReiterated RatingHold$375.00Low
i
Rating by John Newman at Canaccord Genuity
3/29/2017BTIG ResearchReiterated RatingBuy$460.00Medium
i
3/29/2017UBS GroupBoost Price TargetBuy ➝ Buy$435.00 ➝ $446.00N/A
i
Rating by Carter Gould at UBS Group AG
3/28/2017BMO Capital MarketsReiterated RatingHold$408.00 ➝ $412.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
3/28/2017SVB LeerinkSet Price TargetBuy$448.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
3/28/2017Robert W. BairdReiterated RatingNeutral$369.00Low
i
3/20/2017SVB LeerinkReiterated RatingOutperformHigh
i
Rating by Geoff Porges at SVB Leerink LLC
3/20/2017BTIG ResearchReiterated RatingBuy$460.00Low
i
3/17/2017Canaccord GenuityReiterated RatingHold$375.00Low
i
Rating by John Newman at Canaccord Genuity
3/17/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
i
3/16/2017OppenheimerInitiated CoverageHoldHigh
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$435.00N/A
i
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$446.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/16/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralN/A
i
2/16/2017Sanford C. BernsteinReiterated RatingOutperform$420.00 ➝ $410.00N/A
i
2/13/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$359.87 ➝ $446.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
2/11/2017SVB LeerinkSet Price TargetBuy$448.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
2/10/2017Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
2/10/2017Morgan StanleyLower Price TargetEqual Weight$370.00 ➝ $367.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
2/10/2017CitigroupReiterated RatingBuy$420.00N/A
i
2/10/2017Sanford C. BernsteinLower Price Target$410.00N/A
i
2/10/2017Credit Suisse GroupReiterated RatingBuy$485.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
2/9/2017CowenSet Price TargetHold$380.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/6/2017The Goldman Sachs GroupLower Price TargetBuy$448.00 ➝ $446.00N/A
i
2/3/2017Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
1/22/2017JPMorgan Chase & Co.Set Price TargetHold$440.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/11/2017CowenReiterated RatingMarket Perform$400.00 ➝ $380.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/10/2017SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/A
i
1/9/2017Morgan StanleySet Price TargetHold$420.00 ➝ $370.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
1/8/2017Evercore ISISet Price TargetHold$421.00N/A
i
Rating by John Scotti at Evercore ISI
1/8/2017Robert W. BairdReiterated RatingNeutral$379.00 ➝ $369.00N/A
i
1/8/2017BTIG ResearchReiterated RatingBuy$460.00N/A
i
1/6/2017Royal Bank of CanadaReiterated RatingOutperform$626.00 ➝ $598.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
1/6/2017Royal Bank of CanadaLower Price TargetOutperform$626.00 ➝ $598.00N/A
i
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 ➝ $345.00N/A
i
Rating by Gbola Amusa at Chardan Capital
12/28/2016ArgusReiterated RatingBuy$450.00N/A
i
12/20/2016SVB LeerinkSet Price TargetBuy$492.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
12/20/2016BMO Capital MarketsInitiated CoverageMarket Perform$419.00N/A
i
12/20/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$481.00 ➝ $485.00N/A
i
12/16/2016BTIG ResearchUpgradeNeutral ➝ Buy$460.00N/A
i
12/12/2016Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
12/12/2016Robert W. BairdReiterated RatingPositive$379.00N/A
i
12/12/2016Chardan CapitalUpgradeSell ➝ Neutral$300.00 ➝ $350.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
12/5/2016Royal Bank of CanadaSet Price TargetBuy$626.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
12/1/2016SVB LeerinkSet Price TargetBuy$500.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
11/17/2016BTIG ResearchReiterated RatingNeutralN/A
i
11/17/2016Jefferies Financial GroupReiterated RatingHold$394.00N/A
i
11/7/2016Robert W. BairdReiterated RatingNeutral$448.00 ➝ $379.00N/A
i
Rating by Brian Skorney at Robert W. Baird
11/7/2016Chardan CapitalLower Price TargetSell$325.00 ➝ $300.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
11/6/2016Canaccord GenuitySet Price TargetHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
11/6/2016CowenSet Price TargetHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
11/6/2016JPMorgan Chase & Co.Set Price TargetHold$440.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016JPMorgan Chase & Co.Set Price TargetHold$477.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2016CowenSet Price TargetHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
10/30/2016Piper Jaffray CompaniesSet Price TargetHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/25/2016SVB LeerinkSet Price TargetBuy$513.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
10/13/2016Piper Jaffray CompaniesSet Price TargetHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/12/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
10/4/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
10/4/2016Royal Bank of CanadaReiterated RatingOutperform$648.00N/A
i
Rating by adnan butt at Royal Bank of Canada
10/4/2016Robert W. BairdReiterated RatingNeutral$448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
10/3/2016SVB LeerinkSet Price TargetBuy$530.00N/A
i
Rating by geoff porges at SVB Leerink LLC
9/30/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
9/30/2016Chardan CapitalReiterated RatingSell$325.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
9/27/2016The Goldman Sachs GroupReiterated RatingBuy$521.00N/A
i
9/23/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
9/23/2016Robert W. BairdReiterated RatingNeutral$448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
9/21/2016SVB LeerinkReiterated RatingBuy$530.00N/A
i
Rating by geoff porges at SVB Leerink LLC
9/20/2016Piper Jaffray CompaniesReiterated RatingHold$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/9/2016Piper Jaffray CompaniesReiterated RatingNeutral$447.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/17/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/10/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
8/6/2016SVB LeerinkSet Price TargetBuy$530.00 ➝ $511.00N/A
i
Rating by geoff porges at SVB Leerink LLC
8/6/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by adnan butt at Royal Bank of Canada
8/5/2016Roth CapitalReiterated RatingBuy$520.00N/A
i
Rating by Joseph Pantginis at Roth Capital
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/A
i
Rating by Jason Wittes at Brean Capital
8/5/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by John Newman at Canaccord Genuity
8/5/2016Robert W. BairdDowngradeOutperform ➝ Neutral$505.00 ➝ $448.00N/A
i
Rating by Brian Skorney at Robert W. Baird
8/5/2016CowenReiterated RatingHold$430.00N/A
i
Rating by Phil Nadeau at Cowen Inc
7/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/12/2016BTIG ResearchReiterated RatingHoldN/A
i
7/11/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
6/30/2016Sanford C. BernsteinReiterated RatingBuyN/A
i
Rating by Ronny Gal at Sanford C. Bernstein
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$400.00N/A
i
6/23/2016CitigroupReiterated RatingBuy$470.00N/A
i
Rating by Robyn Karnauskas at Citigroup Inc.
6/17/2016Canaccord GenuityReiterated RatingHold$450.00N/A
i
Rating by Reiterated, Today Hold at Canaccord Genuity
(Data available from 6/16/2016 forward)
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $523.58
$522.24
$542.42

50 Day Range

MA: $501.69
$472.80
$532.04

52 Week Range

Now: $523.58
$441.00
$664.64

Volume

912,555 shs

Average Volume

922,338 shs

Market Capitalization

$55.78 billion

P/E Ratio

14.82

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, FIX, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Smith Barney Citigroup, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., and Truist.
View the latest analyst ratings for REGN.

What is the current price target for Regeneron Pharmaceuticals?

18 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $656.11, suggesting a possible upside of 24.7%. The Goldman Sachs Group, Inc. has the highest price target set, predicting REGN will reach $800.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $495.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has 4 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REGN will outperform the market and that investors should add to their positions of Regeneron Pharmaceuticals.
View the latest ratings for REGN.

What other companies compete with Regeneron Pharmaceuticals?

How do I contact Regeneron Pharmaceuticals' investor relations team?

Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is 914-847-7000 and its investor relations email address is [email protected] The official website for Regeneron Pharmaceuticals is www.regeneron.com.